Delinia was founded to discover and develop novel therapeutics for the treatment of autoimmune and inflammatory diseases. Delinia's lead program is a molecule that selectively potentiates and expands regulatory T cells (Tregs), the powerful immune cells that are critical to maintaining self-tolerance and immune system homeostasis. Delinia's scientific founders and experienced executive leaders are working to advance the company's initial programs to the clinic. Delinia is headquartered in Cambridge, Massachusetts with research operations in San Francisco, California.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/14/16 | $35,000,000 | Series A |
Atlas Venture Sofinnova Partners | undisclosed |
